Phibro Animal Health Corporation (PAHC) - Stock Analysis

Last updated: Jan 14, 2026

HealthcareClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Phibro Animal Health exhibits strong earnings growth, margin expansion, cash flow strength, and a 42% price surge over the last month, making it a hot short-term idea with a solid fundamental and technical growth profile.

Loading chart data...

Idea window: 9/2/2025 – 9/9/2025Sector: Healthcare

AI Analyst Overview

Last Price
$41.07
Market Cap
$1664.74
1D Return
+2.52%
YTD Return
+9.93%

Loading chart data...

Valuation Metrics

P/E
24.6
P/B
5.3
P/S
1.2
EV/EBITDA
13.1
Div Yield
1.17%

Fundamental Analysis

8.0

Key Financial Insights: • Improving margins • Elevated leverage • Volatile FCF PAHC shows materially improving margins and strong liquidity but is constrained by high leverage, large inventory and uneven free cash flow, which temper the investment case.

OperationalImprovement
HighLeverage

Price Behavior

6.0

Key Price Behavior Insights: • Downtrend pressure • Failed rallies • Solid floor Support Level: $37.30–$37.80 Resistance Level: $41–$42 PAHC has weakened over the last month from a mid‑November high into a low near $37.30, showing selling pressure with a recent bounce toward $40.46 but stalled at $41–$42 resistance.

cautious
weakness

Sentiment & News

7.0

Key News Insights: • Vaccine growth • CEO succession • Insider/institutional Phibro Animal Health (PAHC) is being flagged as a balanced value-and-growth pick driven by vaccine/animal-health momentum, a planned CEO succession, mixed "Hold" analyst sentiment, and notable insider/institutional trades.

Value
MixedSentiment
AI

AI Summary

6.0
Neutral

PAHC has shifted into a deal-driven integration and margin-recovery story post‑MFA, so the investment now hinges on management's ability to quickly cut inventory, normalize cash conversion and reduce leverage—if they succeed the current multiples (fair value ~\$43) are defendable, but persistent high inventory, lumpy MFA volumes or rising interest costs would materially compress valuation.

Integration
Leverage
CashConversion
AI summary updated 5 days ago

Description

Phibro Animal Health Corporation manufactures and sells a range of animal health and mineral nutrition products for livestock, operating through Animal Health, Mineral Nutrition, and Performance Products segments. Its portfolio includes pharmaceutical treatments and vaccines for poultry, swine and cattle, nutritional additives and trace mineral formulations, plus specialty ingredients used in non-food industries. The company distributes products to integrators, feed manufacturers and distributors across North America, Latin America, Europe, the Middle East, Africa and the Asia Pacific from its headquarters in Teaneck, New Jersey.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Sep 2Sep 9PAHCPhibro Animal Health Corporation
Phibro Animal Health exhibits strong earnings growth, margin expansion, cash flow strength, and a 42% price surge over the last month, making it a hot short-term idea with a solid fundamental and technical growth profile.
Closed+12.8%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.